Cancer Home > Eribulin Medication Information
If you have breast cancer, your healthcare provider may prescribe eribulin mesylate (HalavenTM). This prescription drug is specifically designed for people who have late-stage breast cancer that has not adequately responded to certain other chemotherapy treatments.
Eribulin is administered intravenously (through an IV) and is given on day 1 and day 8 of a 21-day cycle. Fatigue, nerve problems, and low levels of certain white blood cells are some of the possible side effects of this drug.
It's important to review eribulin's safety information with your healthcare provider before starting treatment. This medication may not be suitable for everyone, so make sure your healthcare provider is aware if you have any other medical conditions (such as kidney disease, liver disease, or low blood counts) or if you are taking any other types of medicine (including nonprescription products and herbal supplements).
(For more information on this chemotherapy medication, click Eribulin. This article provides a more in-depth discussion, explaining how eribulin works, what to expect when receiving it, and how to ensure the effectiveness of each dose.)